SGMO – sangamo therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Form 10-K SANGAMO THERAPEUTICS, For: Dec 31
Form 8-K SANGAMO THERAPEUTICS, For: Mar 17
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Davis Gregory D
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Dubois-Stringfellow Nathalie
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Willoughby Scott B.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.